feedback

Faculty

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Associate Medical Director
Sutter Community Hospitals Sleep Laboratory
Sacramento, California


David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy and Clinical Immunology
Co-Director, Asthma Center
Director, Allergy/Immunology Fellowship
Respiratory Institute
Cleveland Clinic
Cleveland, Ohio


Reynold A. Panettieri, Jr, MD
Vice Chancellor, Translational Medicine and Science
Director, Institute for Translational Medicine and Science
Professor of Medicine
Rutgers University
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Jointly Provided By

Activity Details

Free
CME

1.0 AMA PRA Category 1 Credits

Released: March 14, 2017

Expires: March 14, 2018

1 hour to complete

Learning Objectives

  • Characterize the signs and symptoms, disease burden, and unmet medical needs of patients with severe and difficult-to-treat asthma
  • Cite the mechanism of action as well as the safety and efficacy data for new and future biologic therapies for severe and difficult-to-treat asthma
  • Identify the current biomarkers under investigation as well as the phenotypes and endotypes that would assist in appropriately selecting patients and utilizing precision therapy
  • Appropriately manage patients with severe or difficult-to-treat asthma

Target Audience

This activity has been designed to meet the educational needs of physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and pulmonology.

Requirements for Successful Completion

75%

Media

Internet

Conflict of Interest Policy / Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, Novartis (Consulting Fees and Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents).
  • David M. Lang, MD, has affiliations with AstraZeneca, Genentech, Glaxo Smith Kline, Meda, Merck, Novartis (Consulting Fees); Genentech (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); and Genentech, Merck, Novartis (Research).
  • Reynold A. Panettieri, Jr, MD, has affiliations with AstraZeneca, Boston Scientific, Novartis (Consulting Fees); and AstraZeneca, Teva (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
  • Nora Hartley has no affiliations with commercial interests relative to the content to disclose.

Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Technical Support: For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.